2025
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel
Gujarathi R, Peshin S, Zhang X, Bachini M, Meeks M, Shroff R, Pillai A. Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatology Communications 2025, 9: e0743. PMID: 40489757, PMCID: PMC12150937, DOI: 10.1097/hc9.0000000000000743.Peer-Reviewed Original ResearchConceptsBiliary tract cancerManagement of intrahepatic cholangiocarcinomaCirculating tumor DNAIntrahepatic cholangiocarcinomaMolecular testingUnresectable diseaseClinical managementAdvanced biliary tract cancerMolecular profiling of individual tumorsDrug target alterationInsufficient tissue samplesCurative treatment optionCurative intent treatmentPrimary liver malignancyMultidisciplinary team-based approachTissue samplesTissue-based analysisAvailability of tissue samplesLocoregional therapyNegative marginsSurgical resectionTumor DNAAdequate tissueBiliary malignancyClinical presentationWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant difference
2024
Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma
Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma. JHEP Reports 2024, 7: 101294. PMID: 40028344, PMCID: PMC11870164, DOI: 10.1016/j.jhepr.2024.101294.Peer-Reviewed Original ResearchT cell infiltrationHepatocellular carcinomaRadiological-pathological correlationImaging mass cytometryImmune responseT1-weighted MRITumor-infiltrating CD8+ T lymphocytesAnti-tumor immune responseCD8+ T lymphocytesIncreased T lymphocyte infiltrationImaging biomarkersNon-immunogenic tumorsSystemic lymph nodesT lymphocyte infiltrationMurine tumor modelsImmune cell typesLocal tumor therapyPrimary liver cancerNon-invasive imaging biomarkerTesla MRI scannerInduce liver cirrhosisImmunogenic tumorsLocoregional therapySystemic immunotherapyHCC lesionsInterventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology 2024, 313: e232875. PMID: 39560477, PMCID: PMC11605110, DOI: 10.1148/radiol.232875.Peer-Reviewed Original ResearchConceptsManagement of hepatocellular carcinomaHepatocellular carcinomaLocoregional therapyClinical trialsImage-guided locoregional therapiesEnd pointsStages of hepatocellular carcinomaTumor microenvironment mechanismsCatheter-directed therapyCombination of immunotherapyProspective clinical trialImaging end pointsStandard of careAdjuvant settingNovel immunotherapiesCombination therapyTherapy resistanceInterventional radiologistsImmunotherapyDisease stageTherapyDisease evolutionNovel biomarkersCarcinomaMicroenvironment mechanismsSmall Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.Peer-Reviewed Original ResearchSmall cell bladder cancerConcurrent chemoradiotherapyNeoadjuvant chemotherapySEER-Medicare databaseMedian OSLocoregional therapySEER-MedicareBladder cancerHistological subtypesOverall survivalInstitutional databaseCompare outcomesOptimal locoregional therapyAggressive histologic subtypeNon-metastatic stageNon-metastatic diseaseSEER-Medicare datasetMultivariate Cox analysisFollow-up/deathLocalized diseaseCox analysisCystectomyTreatment patternsTreatment responseMultivariate analysisThe survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapy
2023
Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Mendiratta-Lala M, Aslam A, Bai H, Chapiro J, De Baere T, Miyayama S, Chernyak V, Matsui O, Vilgrain V, Fidelman N. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization. European Radiology 2023, 34: 3284-3297. PMID: 37930412, PMCID: PMC11126446, DOI: 10.1007/s00330-023-10326-7.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationTreatment response assessmentEthiodized oilHepatocellular carcinomaTransarterial chemoembolizationTreatment responseResponse assessmentIntermediate-stage hepatocellular carcinomaDuration of responsePortion of tumorPost-treatment imagingTissue drug concentrationsPost-treatment prognosisChemotherapy solutionLiver transplantationLocoregional therapyChemotherapy dosesCombination therapyStandard treatmentTherapy optionsTumor responseImaging appearancesIntraarterial embolizationTumor necrosisTumor vasculatureLocoregional Therapy of Hepatocellular Carcinoma: Reporting Recommendations from the Liver Imaging Reporting and Data System and Society of Interventional Radiology Reporting Committees to Improve Assessment of Response
Roudenko A, Berman Z, Cornman-Homonoff J, Halin N, Kleedehn M, Fowler K, Mendiratta-Lalla M, Chernyak V, Sirlin C, Cunha G. Locoregional Therapy of Hepatocellular Carcinoma: Reporting Recommendations from the Liver Imaging Reporting and Data System and Society of Interventional Radiology Reporting Committees to Improve Assessment of Response. Journal Of Vascular And Interventional Radiology 2023, 34: 2042-2044. PMID: 37557980, DOI: 10.1016/j.jvir.2023.07.032.Peer-Reviewed Original ResearchRadiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial
Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein S, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology 2023, 9: 1083-1089. PMID: 37410451, PMCID: PMC10326730, DOI: 10.1001/jamaoncol.2023.1984.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalDisease-free survivalLocoregional recurrenceBreast-conserving surgeryBreast cancerLocoregional therapyCumulative incidenceRecurrence scoreRadiotherapy informationERBB2-negative breast cancerPredictors of LRRRate of LRRSecondary analysisNode-positive breast cancerBreast Recurrence ScoreLimited nodal diseaseLower locoregional recurrenceOmission of chemotherapyAxillary surgeryRadiotherapy receiptEndocrine therapyN1 diseaseNodal diseaseLocoregional treatmentMenopausal statusAdherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatment
2022
Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?
Wang Y, Strazzabosco M, Madoff DC. Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice? Current Oncology Reports 2022, 24: 1741-1750. PMID: 36255606, PMCID: PMC10878124, DOI: 10.1007/s11912-022-01338-5.Peer-Reviewed Original ResearchConceptsLocoregional therapyIntrahepatic cholangiocarcinomaManagement of ICCFuture prospective randomized studiesComparable survival outcomesSafety of hepatectomyProspective Randomized StudyLocal tumor controlNon-surgical approachCurrent clinical practicePurpose of reviewUnresectable diseaseSurgical candidatesSystemic therapyVenous embolizationRandomized studyTransarterial embolizationDismal prognosisMultimodal treatmentSafety profileSurvival outcomesAblative therapyTumor controlPreoperative hypertrophyLiver lobeIntraarterial Therapies for the Management of Hepatocellular Carcinoma
Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers 2022, 14: 3351. PMID: 35884412, PMCID: PMC9322128, DOI: 10.3390/cancers14143351.Peer-Reviewed Original ResearchDrug-eluting bead transarterial chemoembolizationHepatic artery infusionHepatocellular carcinomaTransarterial therapiesTransarterial chemoembolizationImage-guided locoregional therapiesBead transarterial chemoembolizationCatheter-based treatmentManagement of patientsLocoregional therapyBland embolizationIntraarterial therapyRadioembolization therapyEmbolic agentTherapyChemoembolizationCarcinomaEmbolizationPatientsArteryReviewInfusionTumorsCurrent Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.
Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society Of Clinical Oncology Educational Book 2022, 42: 1-14. PMID: 35486888, DOI: 10.1200/edbk_350442.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaMetastatic headCell carcinomaSystemic therapyFirst-line systemic therapyFirst-line immunotherapyInclusion of chemotherapyImmune checkpoint blockadeNew systemic therapiesNumber of patientsAggressive local managementCombination immunotherapyLocoregional therapyOligometastatic diseaseCheckpoint blockadeNovel immunotherapiesPD-L1Lung metastasesRetrospective studyBiomarker subgroupsCurrent therapiesNeck cancerAblative approachesAntiangiogenic agents
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsRole of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow
Shenoy-Bhangle AS, Tsai LL, Masciocchi M, Arora SS, Kielar AZ. Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow. Abdominal Radiology 2021, 46: 3558-3564. PMID: 33904990, DOI: 10.1007/s00261-021-03094-9.Peer-Reviewed Original ResearchConceptsLiver-directed locoregional therapiesLR-TR algorithmHepatocellular carcinomaLocoregional therapyMultidisciplinary conferenceLiver observationsTreatment of HCCLiver-directed therapiesLiver Imaging ReportingOptimal patient managementPost-treatment imagingRadiologic findingsLiver diseaseOncology patientsTransplant eligibilityInterdisciplinary managementHCC screeningPatient managementMultidisciplinary discussionPatient careImaging ReportingPatientsTherapyRadiologistsDiseaseChemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
Petit C, Lacas B, Pignon J, Le Q, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar M, Lee J, Ghi M, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner M, Vokes E, Hernandez J, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Laskar S, Mazeron J, Jeremic B, Simes J, Zhong L, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P, Groups M, Adelstein D, Agarwal J, Alfonsi M, Argiris A, Aupérin A, Bacigalupo A, Bar-Ad V, Bartelink H, Beadle B, Belkacemi Y, Bensadoun R, Bernier J, Blanchard P, Bourhis J, Bratland Å, Brizel D, Budach V, Budach W, Burtness B, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Cheugoua-Zanetsie M, Cho K, Choussy O, Hernandez J, Denham J, Dobrowsky W, Dominello M, Driessen C, Fallai C, Forastiere A, Fortpied C, Fountzilas G, Garaud P, Garden A, Gery B, Ghadjar P, Ghi M, Laskar S, Graff-Cailleaud P, Grau C, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hay J, Hayoz S, Horiot J, Hitt R, Jeremic B, Johansen J, Jones C, Julieron M, Kristensen C, Kumar S, Lacas B, Langendijk J, Lapeyre M, Lartigau E, Licitra L, Le Q, Lee J, Lee P, Lewin F, Li Y, Lopes A, Lotayef M, Maciejewski B, Mazeron J, Mehta S, Michalski W, Moon J, Moon S, Moyal E, Nankivell M, Nilsson P, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Parmar M, Petit C, Pignon J, Pointreau Y, Posner M, Poulsen M, Quon H, Racadot S, Rosenthal D, Rovea P, Redda M, Sanguineti G, Shenouda G, Simes J, Sharma A, Simon C, Sire C, Skladowski K, Spencer S, Staar S, Strojan P, Stromberger C, Suwinski R, Szutkowski Z, Takácsi-Nagy Z, Tao Y, Temam S, Thomson D, Tobias J, Torres-Saavedra P, Torri V, Tripcony L, Trotti A, Tseroni V, van Herpen C, van Tinteren H, Vermorken J, Viegas C, Vokes E, Waldron J, Wernecke K, Widder J, Wolf G, Wong S, Wu J, Yamazaki H, Zaktonik B, Zackrisson B, Zhong L. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. The Lancet Oncology 2021, 22: 727-736. PMID: 33862002, DOI: 10.1016/s1470-2045(21)00076-0.Peer-Reviewed Original ResearchConceptsOverall survivalLocoregional therapyAdvanced headNeck cancerConcomitant chemotherapyConcomitant chemoradiotherapyIndividual patient data networkNeck squamous cell cancerAltered fractionation radiotherapyNon-metastatic headRole of chemotherapyPlatinum-based chemotherapySquamous cell cancerModalities of treatmentLog-rank testIndividual patient dataCochran's Q statisticInstitut National du CancerP scoreInduction chemotherapyFractionation radiotherapyPrimary endpointHazard ratioHyperfractionated radiotherapySurvival benefitThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice
Chai N, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Seminars In Interventional Radiology 2020, 37: 456-465. PMID: 33328701, PMCID: PMC7732559, DOI: 10.1055/s-0040-1719186.Peer-Reviewed Original ResearchIntermediate-stage hepatocellular carcinomaConventional transarterial chemoembolizationHepatocellular carcinomaLocoregional therapyBland embolizationBarcelona Clinic Liver Cancer (BCLC) staging systemImage-guided locoregional therapiesLiver Cancer staging systemDrug-eluting beads TACEIntermediate-stage diseaseLocoregional treatment optionsImmune checkpoint inhibitorsFirst-line therapyCancer (AJCC) staging systemYttrium-90 RadioembolizationClinical evidence pointsThermal ablationNumber of lesionsCheckpoint inhibitorsDEB-TACELocoregional treatmentSelect patientsSurvival benefitTransarterial chemoembolizationClinical evidenceHepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
Aslam A, Gian R, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World Journal Of Hepatology 2020, 12: 738-753. PMID: 33200013, PMCID: PMC7643220, DOI: 10.4254/wjh.v12.i10.738.Peer-Reviewed Original ResearchTreatment response algorithmLI-RADS treatment response algorithmLocoregional therapyLiver Imaging ReportingHepatocellular carcinomaTreatment response assessmentTreatment optionsResponse assessmentData System treatment response algorithmImaging ReportingDifferent locoregional therapiesLiver transplant candidacyHCC treatment responseTransplant candidacyOverall survivalSystemic therapyTumor burdenLeading causeTreatment responseLI-RADSTumor assessmentEconomic burdenClinical practiceTumor progressionTherapyMolecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment
Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. Clinical Cancer Research 2020, 26: 428-438. PMID: 31582517, PMCID: PMC7244230, DOI: 10.1158/1078-0432.ccr-19-1702.Peer-Reviewed Original ResearchConceptsMR spectroscopic imagingLocoregional therapyLiver cancer microenvironmentConventional transarterial chemoembolizationNew Zealand white rabbitsTumor pHMost liver tumorsZealand white rabbitsMolecular imaging paradigmsPositive therapeutic outcomesTumor residualsTransarterial chemoembolizationTumor devascularizationHistopathologic markersViable tumorSurrogate biomarkerLiver tumorsLiver cancerTumor enhancementLiver parenchymaMetabolic markersMultiparametric MRITherapeutic outcomesHIF-1αVX2 tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply